Patients with heart disease, uncontrolled hypertension or atrial fibrillation require individualized plans
News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
L-ascorbic acid (vitamin C), L-glutamine, magnesium citrate (magnesium), potassium citrate (potassium), beetroot powder concentrate, sweeteners: sucralose, acesulfame K
Those with allergies to any components should avoid it, and it's not recommended for pregnant or nursing women
If the lump results from an injection site reaction, your doctor may recommend supportive treatments
You might also notice an increase in appetite, which is something to be mindful of as you work toward your body composition goals
